CTLA-4 blockade: therapeutic potential in cancer treatments - PubMed (original) (raw)
CTLA-4 blockade: therapeutic potential in cancer treatments
Ahmad A Tarhini et al. Onco Targets Ther. 2010.
Abstract
Enhancing or prolonging T-cell activation by monoclonal antibodies (mAbs) blocking negative signaling receptors such as CTLA4 is one approach to overcoming tumor-induced immune tolerance. Ipilimumab and tremelimumab inhibit CTLA4, prolonging antitumor immune responses and leading to durable anti-tumor effects. Treatment with these mAbs has demonstrated clinically important and durable tumor responses and disease control rates in patients with unresectable advanced melanoma. Durable objective responses have been reported across a spectrum of doses and schedules, with relative safety in this patient population. Although the phase III tremelimumab melanoma study was closed for "futility", the 1-year survival rate of >50% for tremelimumab and the median survival of 11.7 months (compared with 10.7 months for chemotherapy) are notable. Results of the phase III studies testing CTLA4-blockade with ipilimumab are eagerly anticipated. The further development of these agents includes testing in the neoadjuvant melanoma setting (ipilimumab) as well the adjuvant high-risk melanoma setting (ipilimumab). Future progress with CTLA-4 blockade therapy will also likely come from the use of combinations of agents that target several critical regulatory pathways of the immune system and modulate the immune response in the host in a synergistic and controlled fashion.
Keywords: cancer treatment; ipilimumab; monoclonal antibodies; tremelimumab.
Similar articles
- Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J. Weber J. Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Oncologist. 2008. PMID: 19001147 Review. - Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Ribas A, et al. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295794 Free PMC article. Clinical Trial. - CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ, Weber JS, Sondak VK. Phan GQ, et al. Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Epub 2008 Aug 21. Ann Surg Oncol. 2008. PMID: 18716842 Review. - Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA. Retseck J, et al. J Transl Med. 2018 Jul 4;16(1):184. doi: 10.1186/s12967-018-1563-y. J Transl Med. 2018. PMID: 29973204 Free PMC article. - Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Ribas A, et al. J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236. J Transl Med. 2012. PMID: 23171508 Free PMC article. Clinical Trial.
Cited by
- Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.
Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, Kapse P, Gosavi SW, Kundu GC. Kundu M, et al. Mol Cancer. 2024 May 7;23(1):92. doi: 10.1186/s12943-024-01990-4. Mol Cancer. 2024. PMID: 38715072 Free PMC article. Review. - Inflammation and Immunity Gene Expression Patterns and Machine Learning Approaches in Association with Response to Immune-Checkpoint Inhibitors-Based Treatments in Clear-Cell Renal Carcinoma.
Dovrolis N, Katifelis H, Grammatikaki S, Zakopoulou R, Bamias A, Karamouzis MV, Souliotis K, Gazouli M. Dovrolis N, et al. Cancers (Basel). 2023 Nov 29;15(23):5637. doi: 10.3390/cancers15235637. Cancers (Basel). 2023. PMID: 38067341 Free PMC article. - Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.
Yuan Y, Su Y, Wu Y, Xue Y, Zhang Y, Zhang Y, Zheng M, Chang T, Qu Y, Zhao T. Yuan Y, et al. Front Oncol. 2023 Aug 21;13:1229905. doi: 10.3389/fonc.2023.1229905. eCollection 2023. Front Oncol. 2023. PMID: 37671057 Free PMC article. - Recent advances in non-small cell lung cancer targeted therapy; an update review.
Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Araghi M, et al. Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. Cancer Cell Int. 2023. PMID: 37568193 Free PMC article. Review. - Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model.
Yu JL, Jang SR, Liu KY. Yu JL, et al. Cells. 2023 Feb 3;12(3):507. doi: 10.3390/cells12030507. Cells. 2023. PMID: 36766849 Free PMC article.
References
- Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977. - PubMed
- Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–760. - PubMed
- Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484. - PubMed
- Tarhini AA, Kirkwood JM, AM K. Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opin Drug Discov. 2009;4(5):587–603. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources